Neurocrine Biosciences Issues First Expert Consensus for Tardive Dyskinesia in Long-Term Care

Key Facts

1Neurocrine Biosciences presented the first expert consensus recommendations focused on screening, diagnosis, and treatment of tardive dyskinesia in long-term care settings.

2A new analysis of KINECT-PRO data demonstrated meaningful improvements in patients aged 65 and older using INGREZZA (valbenazine) capsules.

3The recommendations were developed through a multidisciplinary Delphi panel to address gaps in managing the disease among older populations.

Neurocrine Biosciences (NBIX) has announced the first-ever expert consensus recommendations for the screening, diagnosis, and treatment of tardive dyskinesia (TD) in long-term care settings. Developed by a multidisciplinary Delphi panel, these guidelines aim to address critical gaps in managing the condition among older populations. Alongside the recommendations, the company shared new analysis from the KINECT-PRO study demonstrating significant clinical improvements in patients aged 65 and older. The data specifically highlights the efficacy of INGREZZA (valbenazine) capsules in treating TD symptoms within this high-risk demographic. This dual announcement reinforces the clinical validity of INGREZZA as a primary treatment option for geriatric patients. Market analysts view this development as a positive step for NBIX, as it expands the drug's clinical footprint in the long-term care market.